Precision BioSciences Sells Gene Editing Business for $50M

TL;DR

PBIO selling gene editing biz for $50M, focusing on therapies. Deal closes Q1 2025.

AI Summary

Precision BioSciences, Inc. announced on January 6, 2025, that it has entered into a definitive agreement to sell its gene editing business to a third party. The company expects to receive approximately $50 million in cash from this transaction, which is anticipated to close in the first quarter of 2025.

Why It Matters

This strategic divestiture allows Precision BioSciences to focus on its ARCUS-based therapies and potentially provides crucial funding for its pipeline development.

Risk Assessment

Risk Level: medium — The sale of a core business unit introduces uncertainty regarding future revenue streams and the success of the remaining therapeutic focus.

Key Numbers

• $50.0M — Sale Proceeds (Cash expected from the sale of the gene editing business.)
• Q1 2025 — Closing Period (Anticipated timeframe for the transaction to be finalized.)

Key Players & Entities

• Precision BioSciences, Inc. (company) — Registrant
• January 6, 2025 (date) — Date of earliest event reported
• $50 million (dollar_amount) — Expected cash proceeds from the sale
• first quarter of 2025 (date) — Anticipated closing period for the transaction

FAQ

Key Financial Figures

• $0.000005 — ch registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital M
• $108.5 million — cts to report that it had approximately $108.5 million in cash, cash equivalents, and restrict
• $2.5 million — December 31, 2024 before the receipt of $2.5 million from TG Therapeutics and other cash inf

Filing Documents

• dtil-20250106.htm (8-K) — 47KB
• 0000950170-25-003290.txt ( ) — 166KB
• dtil-20250106.xsd (EX-101.SCH) — 27KB
• dtil-20250106_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2024, Precision BioSciences, Inc. (the "Company") expects to report that it had approximately $108.5 million in cash, cash equivalents, and restricted cash as of December 31, 2024 before the receipt of $2.5 million from TG Therapeutics and other cash inflows in January 2025. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024, or its results of operations for the year ended December 31, 2024. The audit of the Company's financial statements for the year ended December 31, 2024, by the Company's independent registered public accounting firm is ongoing and could result in changes to the information set forth above. The Company expects that existing cash and cash equivalents, upfront and potential near-term cash from CAR T transactions, along with expected operational receipts, continued fiscal and operating discipline, and availability of Precision's at-the-market ("ATM") facility will extend Precision's cash runway into the second half of 2026. Based on its expected cash runway, the Company believes it is sufficiently capitalized to propel two wholly owned programs through Phase 1 data readouts in 2025 and 2026. The information under Item 2.02 of this Current Report on Form 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Registration statements or other documents filed with the SEC shall not incorporate this information by reference, except as otherwise expressly stated in such filing.

01 Other Information

Item 8.01 Other Information. As previously reported, on January 7, 2024, the Company entered into a License Agreement (the "License Agreement") with TG Cell Therapy, Inc. ("TG Subsidiary") and its parent company TG Therapeutics, Inc. ("TG Parent" and, together with TG Subsidiary, "TG Therapeutics"), pursuant to which the Company granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize non-oncology applications of the Company's allogeneic CAR T therapy azer-cel pursuant to the terms of the License Agreement. In accordance with the terms of the License Agreement, on January 6, 2025, the Company received a deferred cash payment of $2.5 million from, and the Company issued 220,712 shares of its common stock, par value $0.000005 per share, to, TG Subsidiary pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 4(a)(2) thereof.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's expected cash, cash equivalents and restricted cash balances, the sufficiency of the Company's cash runway extending into the second half of 2026, and the Company realizing Phase 1 clinical data for two in vivo gene editing programs. In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "approach," "believe," "contemplate," "could," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "target," "will," "would," or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs and assumptions and on information currently available to the Company. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, without limitation, the Company's ability to procure sufficient funding or other partnership opportunities to advance its programs on terms that are acceptable to the Company, or at all, the progression and success of the Company's programs and product candidates in which the Company expends its resources; the Company's limited ability or inability to assess the safety and efficacy of its product candidates; the risk that other genome-editing technologies may provide significant advantages over the Company's ARCUS technology; the Company's or its collaborators' o

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: January 8, 2025 By: /s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR